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ABSTRACT 
 
 
Background 
Thalassemia is a common public health problem in Malaysia 
and one of the most common chronic and genetic disorders.  
 
Aims 
The present qualitative study explores knowledge about 
thalassemia, perceptions about conventional therapies and 
the points that affect Malaysian patients with thalassemia in 
taking medications correctly. 
 
Methods  
This study used a qualitative method. Purposive and 
theoretical samplings were combined to explore the issues 
related to thalassaemia and its perceptions. Twenty-one 
patients with thalassemia were recruited from the 
Thalassemia Society, Kedah, Malaysia from July to October 
2015. The semi-structured interviews were audio taped, 
transcribed verbatim and translated into English for 
thematic content analysis. 
Results  
Participants perceived thalassemia as an incurable disease 
which is due to genetic and blood related disorders. A 
positive perception was shown towards conventional 
therapies considering it as effective for their condition. High 
treatment cost was given as a reason why patients 
perceived conventional therapies as effective. Fear of side 
effects was the main reason the patients gave for their 
delay in looking for treatment. However, due to limited 
treatment options, patients were reported to show positive 
attitude towards the side effects due to thalassemia 
treatment.  
 
Conclusion 
This explanatory investigation suggests that thalassemia 
patients’ understanding about thalassemia is complex in 
nature. The findings may help healthcare providers remove 
myths about the fear of the treatment. It may also help in 
improving patient’s compliance towards the thalassemia 
therapies. Main focus for future research should be on 
those patients who declined the conventional therapies. 
  
Key Words 
Thalassemia, Malaysia, perceptions, qualitative 
 
What this study adds:  
1. What is known about this subject?  
Thalassemia is the most commonly inherited single gene 
disorder. 
 
2. What new information is offered in this study? 
Information on thalassemia patients’ beliefs and 
experiences regarding thalassaemia and their treatments is 
discussed. 
 
 
 
 104 
 
[AMJ 2016;9(5):103–110] 
 
3. What are the implications for research, policy, or 
practice?  
The findings provide baseline information about patients’ 
knowledge and perceived effectiveness of modern 
treatment which can help to design more specific 
educational program. 
 
Background 
The thalassemia disease is one of the most common genetic 
blood disorders. It is the most commonly inherited single 
gene disorder in the world. Thalassemia is a heterogeneous 
group of genetic disorders resulting in the reduced rate of 
production of one or more of the globin chains of 
haemoglobin while 200,000 affected homozygotes are born 
annually.
1,2
 They are widely distributed worldwide and it is 
estimated that there are 266 million thalassemia carriers 
with three hundred thousand children suffering from 
thalassemia around the world. It is more prevalent in 
certain areas especially among Asians as well as in the 
middle Mediterranean, Middle Eastern and Far Eastern 
populations. In Malaysia, 6,623 patients have been 
registered with the Malaysian Thalassemia Registry 2009. 
From this total number of registered patients, 4,463 (67 per 
cent) of them have been undergoing regular blood 
transfusion and iron chelation treatment.
3
 Every year, 200 
cases are added to the registry. It is anticipated that the 
probability for every new patient to survive would be up to 
30 years. With the statistics of one carrier in every 20 
Malaysians, the Ministry of Health initiated a screening 
program in 2008 which aimed to reduce the birth of babies 
with thalassemia.
4
  
 
Most of the children who are affected live in countries 
where resources are limited. Because of that, emphasis is 
placed more on handling higher rates of infant and child 
mortality rather than infections and malnutrition.
5
 As a 
result, hereditary disorders have received little attention 
and affected children may not receive the treatment they 
need. Eventually, these children end up dying during their 
childhood. Thalassemia is considered a lifelong illness 
requiring biomedical treatment shortly after birth and 
continues until death. Patients with thalassemia usually 
suffer early and late complications secondary to their 
disease. Early complications usually occur in relation to 
blood transfusions while late complications occur due to 
iron overload and underlying poorly treated disease. The 
current study aims to explore the thalassemia patients’ 
experiences and knowledge about thalassemia and to 
explore perceptions towards conventional thalassemia 
therapies. 
 
Methods 
Design and settings 
The study was approved by joint ethical committees of the 
School of Pharmaceutical Sciences, USM and Lam Wah Ee 
Hospital on Clinical Studies in Malaysia [reference: USM-
HLWE/IEC/2015 (002)]. The study was conducted from July 
until October in 2015 at Kedah Thalassemia Society Centre 
in Alor Star in the state of Kedah, in the northern region of 
Peninsular Malaysia. According to Malaysian Thalassemia 
Registry 2014, the northern region had the highest number 
of thalassemia patients in the country. 
 
Participants 
For this study, purposive and theoretical samplings were 
combined to explore the issues related to the perception of 
thalassaemia and its treatment used among thalassemia 
patients.
6 
Patients were purposively selected from three 
major ethnic groups in Malaysia, namely Malay, Chinese 
and Indians. Recruitment was made until we reached 
theoretical saturation i.e. no new information emerged 
after the subsequent interviews thus fulfilling the 
requirement of theoretical sampling.
7
 The participants were 
selected among patients 18 years of age or older who were 
diagnosed with thalassemia disease. The recruitment was 
continued over a period of four months. Informed consent 
was obtained from each respondent by giving patients an 
information sheet in Malay and English to be read prior to 
the interviews. Patients who were unable to read and 
understand these two languages were given verbal 
information. The interview sessions were carried on until 
saturation point was met, that is when there was no new 
information acquired from later interviews. During the four-
month period of data collection, almost 50 patients were 
asked whether they would like to participate in the study. A 
total of 21 patients agreed and were interviewed. The 
reasons given for those who did not participate were 
because of their medical condition and they were not 
available on the interview days.  
  
Study tool 
The interview sessions were carried out using interview 
guide which was formed after extensive literature review. 
Participants were asked about what they know of 
thalassemia, what kind of treatment they seek, and the 
options they have for thalassemia treatment. The questions 
given during the interview sessions were kept open-ended 
as much as possible in order to give the participants the 
greatest possible chance to give their views. Initially, four 
interview sessions were conducted in Jun 2015 as a pilot 
study in order to detect any problems or challenges 
associated to the interview to ensure that the study could 
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be conducted appropriately and also to modify interview 
guide if necessary.
8
 
 
Data collection and data analysis procedures  
Each semi-structured in-depth interview session lasted 
approximately for 45 to 60 minutes. Interviews were 
conducted in the Malay language. One-to-one interviews 
were conducted, thus having one patient per session. A 
total of 21 interviews were conducted. We reached 
saturation at 19
th 
interview; however, two extra interviews 
were conducted to confirm the findings. The interviews 
sessions were recorded digitally and transcribed in English 
by the principal investigator. To ensure privacy, the identity 
of participants was kept confidential by using an identified 
unique number (P01 to P21). The principal investigator was 
present during the entire interview sessions.  
 
The interview sessions were transcribed verbatim. The 
transcripts were reviewed and sent to the participants for 
approval. The transcripts were subjected to thematic 
content analysis including coding and identification of 
common or recurrent themes using comparative analytic 
process to identify emerging categories. This was done by 
the principal investigator and the co-researchers who were 
informed about the aims and objectives of this study. The 
data was further analyzed to assess the behaviour of each 
participant based on the unique codes.
9,10
 The principal 
investigator and the participants in the study shared a 
similar cultural background, spoke Malay and English in the 
Kedahan dialect. Hence, the principal investigator did not 
experience any communication barrier.  
 
Results 
Twenty-one patients (P01-P21) between the ages of 18 and 
58 (Mean = 29 years) were interviewed. Because the Malays 
constitute the main ethnic group in Malaysia, they made up 
the highest (n=17) number of patients in the sample groups, 
followed by the Chinese (n=4). Most of the participants 
were from low-income group getting treatment in 
government hospitals. All of the patients, who were β 
thalassemia major and intermediate thalassemia, had no 
health insurance, and they had no other choice than to go 
to government hospitals for treatment. The demographic 
data are summarized in Table 1. During the analysis, three 
categories were identified beliefs regarding the causes of 
thalassemia, beliefs in the benefits of modern treatment, 
and experiences related to the side effects of modern 
treatment. Conventional or modern treatment for this study 
was those widely used in the modern health care system. 
The conventional treatment offered by hospital includes 
blood transfusion, surgery and chelation therapy. 
Traditional ways of healing includes any treatment other 
than what has been offered by the hospitals.  
Beliefs regarding the causes of thalassemia 
When asked about thalassemia and why they had 
thalassemia, the participants gave different reasons 
according to the following subthemes: blood disease, 
genetic disorder, and spiritual coping mechanism.  
 
Table 1: Demographic and disease characteristic of 
participants 
Characteristic N=21 % 
Age (Mean= 29) 
18-30 13 62 
31-40 7 33 
41-50 0 0 
51-60 1 5 
Gender 
Male 6 29 
Female 15 71 
Race 
Malay 17 81 
Chinese 4 19 
Religion 
Islam 17 81 
Buddhism 4 19 
Educational Status 
Primary 2 10 
Secondary 12 57 
Diploma /Matriculation 7 33 
Socioeconomic Status * 
Low (less than 
RM1000/month) 
13 62 
Middle (RM 1000–
3000/month) 
8 38 
High (> RM 3000/month) 0 0 
Medical Insurance 
Yes 2 10 
No 19 90 
Marital Status 
Single 13 62 
Married 7 33 
Divorce 1 5 
Type of Thalassemia 
β -Thalassemia Major 13 62 
IntermediateThalassemia 6 29 
Thalassemia Minor 
(Trait) 
2 10 
[*Sources: Department of Statistic Malaysia, Official Portal 
2015] 
 
Blood disease 
In this exploratory investigation, patients described 
thalassemia as only related to blood and could not be cured. 
“I do not know anything about thalassemia. I only know that 
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it is something that is related to blood”. [P10, 23 years, 
female, Malay, β-thalassemia major] 
 
“I only know that every month, I need blood or else I will be 
sick”. [P19, 19 years, male, Chinese, β-thalassemia major] 
 
Thalassemia patients reported themselves as dependent on 
blood transfusion. 
 
“It is a blood disease. The blood needs to increase every 
month”. [P5, 22 years, female, Malay, Intermediate 
thalassemia] 
 
“Thalassemia is a disease where the red blood cell will burst 
in less than a month causing the person to be tired”. [P9, 19 
years, female, Malay, Intermediate thalassemia] 
 
It was observed that patients understood thalassemia as a 
disease inherited from parents with thalassemia genes. It 
was found that blood transfusion is the most important 
treatment to those with thalassemia, especially β-
thalassemia major and intermediate thalassemia patients, 
as this treatment would provide blood with normal 
haemoglobin to the patients in order to maintain the 
amount of red blood cells in the body. 
 
Genetic disorder 
Patients who have a history of thalassemia running in the 
family had a strong belief that thalassemia is a genetic 
disease. 
 
“It is a genetic disease and I got it from my parents”. [P5, 22 
years, female, Malay, Intermediate thalassemia] 
 
“I only know that it is an inherited disease because I got it 
from my parents, both of whom are carriers”. [P12, 32 
years, Female, Malay β-thalassemia major] 
 
“I am a β -thalassemia major patient. I know that it is an 
inherited disease and it is related to blood. But my parents 
are not carriers. May be it came from my grandpa”. [P16, 26 
years, Female, Malay, β-thalassemia major] 
 
Those who considered thalassemia as a genetic disorder 
showed their concerns towards the importance of 
screening. Patients perceived that early screening can 
benefit them. By knowing the severity of the disease, they 
can take appropriate actions.  
 
“Now, my child is a β-thalassemia major. I often bring him to 
the hospital for treatments. Everybody loves their children 
including my parents. But, they are no more. They always 
care for me when they were alive. I don’t know I am a 
carrier until and I feel that my thalassemia is not as serious 
as my child”. (P18, 57 years, Chinese, carrier) 
 
Spiritual coping mechanism  
Spiritual connection was found among all of the thalassemia 
patients. They were able to deal with it by having strong 
faith in their own respective religions. 
 
“Thalassemia disease makes me closer to Allah Subhanahu 
wa Ta’ala (SWT). To remain calm and maintain my 
composure, I have sought solace and become closer 
spiritually with Allah and prayed Dhuha prayer”. [P7, 29 
years, Female, Malay, β-thalassemia major] 
  
“I also do a lot of extra prayers, reciting the Qur’an and 
‘dzikr’. I feel that these bring me closer to Allah S.W.T.”. 
[P10, 23 years, Female, Malay, β-thalassemia major] 
 
“We need to accept the destiny and if it is God’s will, then it 
will happen”. [P21, 38 years Female, Chinese, carrier]  
 
Most of the patients were Muslims and they felt that their 
sickness brought them closer to Allah S.W.T. It was found 
that most of the patients had the tendency to engage in 
more on spiritual development practices such as praying 
rather than merely physical exercises such as aerobics and 
going to spa as coping strategies for their ailments. 
 
Beliefs in the benefits of modern treatment 
Positive views regarding modern treatment 
 
Backed by evidence from research 
Participants had different perceptions regarding the 
effectiveness of conventional therapies. Thalassemia 
patients were satisfied with the current quality of the 
treatment of thalassemia compared to that of the previous 
years. They believed their thalassemia symptoms could be 
reduced by undergoing the therapies. Advanced new 
technologies for thalassemia treatment were the reasons 
given by the patients.  
 
 “I think that modern treatment is good and effective for my 
sickness”. [P1, 38 years, female, Malay, Intermediate 
thalassemia] 
 
“I believe that modern treatment is effective and I have been 
receiving treatment ever since I was a kid. If not, I would not 
have been able to do any work. I will depend on blood 
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transfusion, folic acid, dysferal and exjade”. [P4, 24 years, 
female, Malay, β-thalassemia major] 
 
“I believe in the effectiveness of the modern treatment 
because it works faster and is more effective even though 
those suffering from thalassemia cannot be cured. Modern 
treatment comes with evidence from research compared to 
the lack of evidence from the traditional ones. Today, the 
current conventional treatment is more effective compared 
to that of the previous years”. [P10, 23 years, female, Malay, 
β-thalassemia major] 
 
Modern treatment 
Modern treatment for thalassemia is provided by hospitals. 
The patients perceived modern therapies as effective. 
Thalassemia patients would need to follow all the 
regulations given by the hospital, such as the schedule of 
blood transfusion and the medicines needed to be taken, in 
order to make sure the symptoms would be reduced. They 
perceived this as deficient in the traditional ways of healing.  
 
Patients believed that the treatment they received was very 
effective especially in increasing their hemoglobin level in 
their blood compared to the traditional way which would be 
very time-consuming. For example, the iron chelation 
therapy treatment, that would eliminate iron after blood 
transfusion, would be way better than the traditional way 
which would have no specific ways of eliminating iron in the 
body. 
 
 “To me, the hospital’s treatment works. I know that each 
treatment undergone is important but I do not know what 
the outcome of this continuous process is”. [P5, 22 years, 
female, Malay, β-thalassemia major] 
 
“I feel that taking medicines is effective. If I do not take the 
prescribed medicines, I am unable to work especially after 
having the blood transfusion”. [P6, 36 years, female, Malay, 
Intermediate thalassemia] 
 
Treatment Cost 
One of the reasons why patients thought modern treatment 
is effective was because of its cost which is expensive.  
 
“I believe in the effectiveness of the modern treatment 
because it works faster and is very expensive. Before this, we 
had to buy our own filter bag, unlike these days. It is more 
effective even though those suffering from thalassemia 
cannot be cured”. [P10, 23 years, female, Malay, β-
thalassemia major] 
 
Negative views regarding modern treatment 
The patients were constantly concerned about the adverse 
effects and they were also worried if the treatment would 
turn out to be a failure. Therefore, there were patients who 
felt that it was not worthwhile taking the conventional 
treatment. 
 
“Antibiotics don’t work. I am still sick…. I had to be warded 
for 5 months, unconscious due to brain infection or brain 
abscess. Doctor said that it was because of the blood 
transfusion done on me”. [P1, 38 years, female, Malay, 
Intermediate thalassemia] 
 
“For the blood transfusion, I am a bit worried whenever I 
think of the possible risks of getting infected with HIV and 
many more. But, gradually, I have got used to it. Now, 
whenever it crosses my mind, I quickly pray and hope for the 
best”. [P12, 32 years, female, Malay, β-thalassemia major] 
 
“Each time I take my dysferal, I feel weak and I am unable to 
do much work. We are always in pain from the needles but if 
we don’t take it, we are dead.” [P2, 26 years, male, Malay, 
β-thalassemia major] 
 
“Taking dysferal caused me to be down with fever and L1 
(deferiprone) caused me nausea and vomiting”. [P7, 29 
years, female, Malay, Intermediate thalassemia] 
 
All of the participants were patients who had been receiving 
treatment from the hospital and they might have their own 
perceptions about the treatment they had undergone there, 
the effectiveness of the medicines and the modern 
treatment they had tried. However, there were some of 
them who compared traditional treatment with modern 
treatment they had undergone which did not give the 
outcomes they had hoped for. As a result, they did not 
follow the treatment nor take the medicines given by the 
hospital causing harm to their heart, liver and other organ 
failures due to inability to eliminate excessive iron in the 
body. 
 
Experiences related to the side effects of modern treatment  
 
Fear of blood transfusion 
Most participants were worried about the side effects from 
blood transfusion and iron chelation therapy. Other major 
worries included the chances of them getting infections 
from viruses and bacteria. The participants were also 
frightened from serious co-morbidities such as 
cardiomyopathy. A strong disapproving view was noticed 
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among thalassemia patients where there was an increased 
level of anxiety each time after blood transfusion.  
 
“My liver often swells maybe due to the frequent blood 
transfusion each month. My spleen often swells too. 
Sometimes I wonder if I keep on doing blood transfusion, am 
I going to be infected with Hepatitis C virus for example, 
because many of those with thalassemia got hepatitis C”. 
[P5, 22 years, Female, β-thalassemia major] 
 
 “Each time I have to do blood transfusion, I am worried that 
I will get infected by HIV, Hepatitis C and Hepatitis B”. [P2, 
26 years, male, Malay, β-thalassemia major] 
 
“When he took the supplements, he looked energetic and 
healthier. I feel that taking the alternative treatments is a 
way for me to stop him from taking medicines that can be 
harmful to him because I could see the change and 
improvements in him”. [P21, 38 years, female, Chinese, 
carrier] 
 
Most of the participants revealed their deep sense of 
awareness of their health and implications to their lives. The 
patients tried to seek other medicines in place of their 
modern treatment because they were afraid of the side 
effects of the medicines taken continuously in the future. 
 
Fear of iron chelation therapy 
The fear of the side effects of modern treatment was 
associated with co-morbidities. Many of the participants 
reported that they had many symptoms and side effects 
caused by the conventional treatment. The patients felt 
difficult to comply with the treatment because of the 
several factors such as side effects and fear of the 
subcutaneous injection of the iron chelation therapy. 
 
“I vomit frequently after taking exjade and then changed to 
L1. Injecting dysferal causes my skin to itch. My spleen had 
been removed. Then I took penicillin. I am easily tired 
because I have to take injections often. I often tried to 
escape from getting treatments until I am really not well. If I 
take medicines, I will sleep all day because the medicines 
make me feel sleepy. It is very tiring and boring to inject my 
own self every day and every night. Any alternative 
treatment, I will try it because I do not want to continue this 
treatment my whole life and keep on depending on 
medicines. I do not want it to interfere with my life”. [P15, 
24 years, male, Malay, β thalassemia major] 
 
“I swell, itch and hurt each time after injecting dysferal. I 
take 4 bottles of dysferal each day for 5 days. After blood 
transfusion I will get a fever. My liver swells up to 8mm. I 
need blood. If I do not transfuse blood, I cannot do anything 
at all. I do not know the exact details of what medicines I 
took will give what results. Doctor told me to take it and I 
did. I took the medicines because I feel that it is essential for 
my disease but I always delay to take the medication. I 
cannot comply with all medication. I had taken exjade but I 
vomit each time after taking it. And sometimes, my body will 
get itchy too”. [P13, 30 years, male, Malay, β-thalassemia 
major] 
 
“Having injected dysferal 4 bottles a day for 6 days straight 
sometimes makes me difficult to move and my skin would 
become itchy”. [P10, 23 years, female, Malay, β-thalassemia 
major] 
 
“If I take the medicines, I will sleep all day because the 
medicines make me feel sleepy. It is very tiring and 
frustrating having to inject oneself every day and every 
night”. [P15, 24 years, male, Malay, β-thalassemia major] 
 
Fear of surgery 
The patients who participated in the study were also afraid 
about the possibility of them having to undergo surgery and 
organ removal. They had loss of confidence in the medicines 
of thalassemia treatment because it failed to treat the 
illness and some other reasons were provided by the 
patients to explain why they delayed or avoided getting 
conventional treatments. 
 
“I had to remove my spleen because it had been swollen due 
to the continuous blood transfusion done on me”. [P8, 
female, Malay, β-thalassemia major] 
 
“But if I can get better treatment, for instance the 
traditional way, I would stop undergoing the treatment I am 
doing now as I am not sure of its consequences if I continue 
with this treatment”. [P13, 30 years, Male, Malay, β-
thalassemia Major] 
 
“I am worried that my son might have to undergo the spleen 
removal operation next. My husband and I are worried 
about the side effects and that is why we strive to look for 
the best way to heal our child and we have already spent a 
lot of money to buy supplements rather than depend only on 
hospital medication”. [P20, 38 years, male, Chinese, carrier] 
 
Positive views about the side effects of modern treatment 
Although the patients had some misconception of the 
conventional treatment, a majority of the participants 
showed their commitment with the treatment and coped 
with the general side effects after the treatment; because 
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they had received the treatment since their childhood and 
that it was the only means for them to survive.  
 
Their statements seem to suggest that they do not have 
much choice if they want to continue their lives as normal 
people. 
 
“I have to undergo all of the treatment in order to live and I 
have to take the extra supplements to live like normal 
people”. [P2, 26 years, male, Malay, β-thalassemia major] 
 
“I feel that taking medicines is effective. If I do not take the 
prescribed medicines, I am unable to work especially after 
having the blood transfusion”. [P6, 36 years, female, Malay, 
Intermediate thalassemia] 
 
“I believe in the effectiveness of the modern treatment 
because it works faster compared to the traditional 
treatment. The cost of conventional treatment is much 
higher compared to that of the traditional one. The 
government has spent a lot of money for the thalassemia 
patients”. [P11, 20 years, female, Malay, Intermediate 
thalassemia] 
 
Fear of the symptoms and effects of thalassemia treatment 
such as blood transfusion, chelation therapy such as 
dysferal and exjade were the main factors that drove 
patients to find other forms of alternative treatment. 
However, for the thalassemia patients, they needed to get 
the treatment to continue their lives as normal people 
because the thalassemia patients were dependent on blood 
transfusion. The perceptions of the participants was one of 
acceptance for the fears and side effects because blood 
transfusion was the mainstay of treatment for individuals 
with thalassemia major and many with thalassemia 
Intermediate. Patients needed to continue with the modern 
therapy. However, the side effects of the modern 
medication and its treatment should be reduced as much as 
possible and must be supported with proper counselling 
and social support. 
 
Discussion 
The aim of this study was to look into the views of 
thalassemia patients regarding thalassemia, as well as to 
gain an in-depth understanding of their experiences which 
are related to modern thalassemia treatment. The present 
study represented a diverse group of thalassemia patients 
in terms of age, ethnic background and types of 
thalassemia. It is the most common chronic and genetic 
blood disorder in the world.
11
 Despite the therapeutic 
efforts, patients would encounter a variety of physical and 
physiological problems.
12
 Most of the participants admitted 
having inherited thalassemia from their parents because of 
genetic factor. Generally, the probability of people doing 
screening activities for thalassemia would be contingent 
upon how much they found themselves at risk of getting 
thalassemia and they would also not know why exactly they 
have got thalassemia. 
 
Thalassemia at present is one of the most challenging 
haematological disorders with no permanent cure. Patients 
with the β-thalassemia major need regular blood 
transfusions in order to live and the result of iron overload 
requires chelation therapy. In a developing country like 
India, the main cause of death from thalassemia is because 
of noncompliance with the treatment related to 
psychological factors.
13
 It can be said that the acceptable 
and effective ways to avoid cases of thalassemia are carrier 
screening and genetic counselling among people with high 
risks.
11
 Despite belonging to two different groups of 
religions, Muslim and Buddhist patients both acknowledged 
that diagnosis of thalassemia had brought them closer to 
God. The patient involved in the study reported various 
methods of handling thalassemia. For example, for Muslims 
patients they coped with it by reciting verses from the 
Quran, the Holy Book for the Muslims. 
 
The results of the study suggested that the treatment 
perceptions including fear of side effects may affect 
patient’s decision to use or to forgo modern treatments. 
The good development of prognosis and the treatment have 
prolonged the expectation of life among thalassemia 
patients. The patients showed a satisfactory level of 
awareness and knowledge about modern therapy. The 
patients perceived the modern treatment positively 
because it had been scientifically proven by research. Based 
on the interview transcripts, numerous themes emerged 
with regard to the perceived effectiveness of traditional 
medicines for thalassemia. In a study in Turkey, it was found 
that 1 of every 2 parents of thalassemia patients had used 
complementary and alternative medicine (CAM) in treating 
their children, and mostly had used more than one type of 
CAM.
13
 Further analysis of the participants could be added 
on to these perceptions.  
 
In the present study, thalassemia participants perceived 
that the modern treatment was effective, despite the high 
cost of the treatment, and that they would comply with the 
treatment. Furthermore, fears of the side effects of the 
treatment such as blood transfusion, iron chelation therapy, 
surgery and the medication given were also the reasons of 
noncompliance and delay in seeking treatment. The 
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complication of iron overload included growth retardation 
and failure as well as delay in sexual maturation among 
children. It is also related to complications involving the 
heart, liver and endocrine glands.
15 
 
Limitation 
Because of financial constraint, the study was carried out 
only in one region in Malaysia. However, serious attempts 
were made to involve patients ranging from different 
ethnic, educational and socio-economic backgrounds, and 
also having different types of thalassemia. These attempts 
may have helped to generalise the data as much as possible. 
 
Conclusion 
This qualitative explanatory study explored thalassemia 
patients’ beliefs and perceptions towards their treatment. 
Finding comfort in religious practices was found to be useful 
for patients with thalassemia to cope with their problem. 
The findings of this study provided some understanding of 
thalassemia, and the views of thalassemia patients 
regarding modern treatment, which can be valuable in 
designing more effective educational and intervention 
programmes.  
 
Each thalassemia patient’s beliefs regarding the treatment 
they undertake play an important role in persuading them 
to comply with the treatment diligently, and consistently 
take their medicines without missing even a single dose 
since it may bring negative implications. Having a 
conference or symposium approach may reduce the risk of 
patients who do not undergo treatment and take their 
medicines seriously since they would be exposed to the 
importance of the medicines and treatment undertaken. 
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